294 related articles for article (PubMed ID: 23658320)
1. Fractional anisotropy of the optic radiations is associated with visual acuity loss in optic pathway gliomas of neurofibromatosis type 1.
de Blank PM; Berman JI; Liu GT; Roberts TP; Fisher MJ
Neuro Oncol; 2013 Aug; 15(8):1088-95. PubMed ID: 23658320
[TBL] [Abstract][Full Text] [Related]
2. Validation of an automated tractography method for the optic radiations as a biomarker of visual acuity in neurofibromatosis-associated optic pathway glioma.
de Blank P; Fisher MJ; Gittleman H; Barnholtz-Sloan JS; Badve C; Berman JI
Exp Neurol; 2018 Jan; 299(Pt B):308-316. PubMed ID: 28587872
[TBL] [Abstract][Full Text] [Related]
3. Feasibility and comparison of visual acuity testing methods in children with neurofibromatosis type 1 and/or optic pathway gliomas.
Avery RA; Bouffet E; Packer RJ; Reginald A
Invest Ophthalmol Vis Sci; 2013 Feb; 54(2):1034-8. PubMed ID: 23329671
[TBL] [Abstract][Full Text] [Related]
4. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.
Balcer LJ; Liu GT; Heller G; Bilaniuk L; Volpe NJ; Galetta SL; Molloy PT; Phillips PC; Janss AJ; Vaughn S; Maguire MG
Am J Ophthalmol; 2001 Apr; 131(4):442-5. PubMed ID: 11292406
[TBL] [Abstract][Full Text] [Related]
5. Optic pathway gliomas in patients with neurofibromatosis type 1: follow-up of 44 patients.
Segal L; Darvish-Zargar M; Dilenge ME; Ortenberg J; Polomeno RC
J AAPOS; 2010 Apr; 14(2):155-8. PubMed ID: 20451859
[TBL] [Abstract][Full Text] [Related]
6. Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.
de Blank PMK; Fisher MJ; Liu GT; Gutmann DH; Listernick R; Ferner RE; Avery RA
J Neuroophthalmol; 2017 Sep; 37 Suppl 1(Suppl 1):S23-S32. PubMed ID: 28806346
[TBL] [Abstract][Full Text] [Related]
7. Delineation of the visual pathway in paediatric optic pathway glioma patients using probabilistic tractography, and correlations with visual acuity.
Hales PW; Smith V; Dhanoa-Hayre D; O'Hare P; Mankad K; d'Arco F; Cooper J; Kaur R; Phipps K; Bowman R; Hargrave D; Clark C
Neuroimage Clin; 2018; 17():541-548. PubMed ID: 29527480
[TBL] [Abstract][Full Text] [Related]
8. Visual acuity of children treated with chemotherapy for optic pathway gliomas.
Kalin-Hajdu E; Décarie JC; Marzouki M; Carret AS; Ospina LH
Pediatr Blood Cancer; 2014 Feb; 61(2):223-7. PubMed ID: 23956233
[TBL] [Abstract][Full Text] [Related]
9. The Use of Magnetic Resonance Imaging Screening for Optic Pathway Gliomas in Children with Neurofibromatosis Type 1.
Prada CE; Hufnagel RB; Hummel TR; Lovell AM; Hopkin RJ; Saal HM; Schorry EK
J Pediatr; 2015 Oct; 167(4):851-856.e1. PubMed ID: 26233602
[TBL] [Abstract][Full Text] [Related]
10. Long-term visual outcomes of optic pathway gliomas in pediatric patients without neurofibromatosis type 1.
Wan MJ; Ullrich NJ; Manley PE; Kieran MW; Goumnerova LC; Heidary G
J Neurooncol; 2016 Aug; 129(1):173-8. PubMed ID: 27311725
[TBL] [Abstract][Full Text] [Related]
11. Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials.
Chang BC; Mirabella G; Yagev R; Banh M; Mezer E; Parkin PC; Westall CA; Buncic JR
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2895-902. PubMed ID: 17525226
[TBL] [Abstract][Full Text] [Related]
12. Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.
Dotto PF; Berezovsky A; Cappellano AM; da Silva NS; Sacai PY; Silva FAB; Fernandes AG; Rocha DM; Salomão SR
Doc Ophthalmol; 2018 Jun; 136(3):177-189. PubMed ID: 29766345
[TBL] [Abstract][Full Text] [Related]
13. Visual outcomes in children with neurofibromatosis type 1-associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis.
Fisher MJ; Loguidice M; Gutmann DH; Listernick R; Ferner RE; Ullrich NJ; Packer RJ; Tabori U; Hoffman RO; Ardern-Holmes SL; Hummel TR; Hargrave DR; Bouffet E; Charrow J; Bilaniuk LT; Balcer LJ; Liu GT
Neuro Oncol; 2012 Jun; 14(6):790-7. PubMed ID: 22474213
[TBL] [Abstract][Full Text] [Related]
14. Investigation of retinal nerve fiber layer thickness and ganglion cell layer-inner plexiform layer thickness in patients with optic pathway gliomas.
Hepokur M; Sarici AM
Graefes Arch Clin Exp Ophthalmol; 2018 Sep; 256(9):1757-1765. PubMed ID: 29754292
[TBL] [Abstract][Full Text] [Related]
15. The Relationship Between Choroidal Abnormalities and Visual Outcomes in Pediatric Patients With NF1-Associated Optic Pathway Gliomas.
Estrela T; Truong S; Garcia A; He J; Ying GS; Devakandan K; Reginald YA; Fisher MJ; Liu GT; Ullrich NJ; Avery RA; Heidary G
J Neuroophthalmol; 2024 Mar; 44(1):5-9. PubMed ID: 38252486
[TBL] [Abstract][Full Text] [Related]
16. Systemic Chemotherapy and White Matter Integrity in Tracts Associated with Cognition Among Children With Neurofibromatosis Type 1.
de Blank PM; Berman JI; Fisher MJ
Pediatr Blood Cancer; 2016 May; 63(5):818-24. PubMed ID: 26757156
[TBL] [Abstract][Full Text] [Related]
17. Optic pathway glioma in children: does visual deficit correlate with radiology in focal exophytic lesions?
Aquilina K; Daniels DJ; Spoudeas H; Phipps K; Gan HW; Boop FA
Childs Nerv Syst; 2015 Nov; 31(11):2041-9. PubMed ID: 26277358
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors of neurofibromatosis type 1-associated optic pathway gliomas in children].
Florent C; Beylerian M; Mairot K; Dambricourt L; André N; David T; Girard N; Audic F; Denis D
J Fr Ophtalmol; 2022 Feb; 45(2):173-184. PubMed ID: 34972579
[TBL] [Abstract][Full Text] [Related]
19. Neurofibromatosis Type 1-Associated Optic Pathway Glioma in Children: A Follow-Up of 10 Years or More.
Kinori M; Armarnik S; Listernick R; Charrow J; Zeid JL
Am J Ophthalmol; 2021 Jan; 221():91-96. PubMed ID: 32283094
[TBL] [Abstract][Full Text] [Related]
20. Effect of age and neurofibromatosis type 1 status on white matter integrity in the optic radiations.
de Blank P; Berman JI; Prelack M; Sollee JR; Lane A; Waldman AT; Fisher MJ
Neurooncol Adv; 2020 Jul; 2(Suppl 1):i150-i158. PubMed ID: 32642741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
